Literature DB >> 25398246

A novel approach for establishing cardiovascular drug efficacy.

Hiddo J Lambers Heerspink1, Diederick E Grobbee2, Dick de Zeeuw1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25398246     DOI： 10.1038/nrd4090-c2

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Hans-Henrik Parving; Peter Rossing; Hiddo Jan Lambers Heerspink
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

2.  Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform.

Authors:  Hiddo J L Heerspink; Vlado Perkovic
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-26       Impact factor: 8.237

3.  Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Authors:  Sergei Petrykiv; C David Sjöström; Peter J Greasley; John Xu; Frederik Persson; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 8.237

4.  Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Paul A Smink; Dennis Andress; John J Brennan; Blai Coll; Ricardo Correa-Rotter; Fan Fan Hou; Donald Kohan; Dalane W Kitzman; Hirofumi Makino; Hans-Henrik Parving; Vlado Perkovic; Giuseppe Remuzzi; Sheldon Tobe; Robert Toto; Jarno Hoekman; Hiddo J Lambers Heerspink
Journal:  Eur J Prev Cardiol       Date:  2015-07-30       Impact factor: 7.804

5.  Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.

Authors:  Marcel H A Muskiet; Lennart Tonneijck; Mark M Smits; Mark H H Kramer; D Margriet Ouwens; Bolette Hartmann; Jens J Holst; A H Jan Danser; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2021-10-06       Impact factor: 6.408

Review 6.  Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

Authors:  Markus Hinder; B Alexander Yi; Thomas H Langenickel
Journal:  Clin Pharmacol Ther       Date:  2018-02-01       Impact factor: 6.875

7.  Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Authors:  Nienke M A Idzerda; Bergur V Stefansson; Michelle J Pena; David C Sjostrom; David C Wheeler; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2020-09-01       Impact factor: 5.992

8.  Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.

Authors:  Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

9.  Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Authors:  Jeroen V Koomen; Jasper Stevens; Hiddo J L Heerspink
Journal:  Br J Clin Pharmacol       Date:  2020-05-10       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.